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ABSTRACT
Alteration of the Adenylate Cyclase System
in Specific Regions of Brain Infected with
Creutzfeldt-Jakob Disease
Susan Ann Valley
1988
Creutzfeldt-Jakob (CJD) disease is an infectious,
progressive neurological disorder which results in human
dementia. Synaptic membranes from various brain
regions of guinea pigs and hamsters infected with
Creutzfeldt-Jakob disease show increased guanyl
nucleotide mediated activation of adenylate cyclase
which appears to be due to a greater coupling of
stimulatory subunits (Ns) and not to a decreased coupling
of inhibitory subunits (Ni) or to a change in the catalytic
subunit of adenylate cyclase. In addition to the increase
in Ns coupling, CJD infected membranes appear to be
more fluidized than normal membranes especially in the
cerebral cortex. Experiments with selected
neurotransmitters and neuropeptides indicate that a sub-
population of cyclases (dopamine specific) are involved in
the CJD effect. It is possible that these effects are due to
the direct action of the CJD infectious agent, or a
pathological product resulting from that agent, upon
synaptic membrane adenylate cyclase.
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INTRODUCTION
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Stimulation or inhibition of adenylate cyclase (AC) by
hormones or neurotransmitters is a complex process (see
Appendix B) involving transduction of several different stimuli
into one common intracellular signal thereby permitting
summation of these signals. Such a process involves a large
number of complex interactions which take place in the plane
of the membrane. Several protein components and
surrounding lipids of the membrane are responsible for
changes in signal transduction.
Adenylate cyclase has been shown to be important in
memory; alteration of the intracellular regulation of this
enzyme results in decreased learning ability (18). Since a
decline in cognitive and memory function are among the
characteristic clinical findings in human victims of Alzheimer's
disease and in the transmissible spongiform encephalopathy
Creutzfeldt-Jakob disease (CJD), it is possible that alteration of
adenylate cyclase components may be responsible for the
decline in memory function of patients with these diseases.
Whether this alteration is the result of a transmissible agent
(especially in the case of CJD) or agent triggered changes in the
membrane composition remains to be elucidated.
Alterations in neurotransmitters have also been shown in
dementing illnesses including Alzheimer's disease and
spongiform encephalopathies (including CJD and scrapie, see
Appendix A). Changes in choline acetyltransferase are well
documented in Alzheimer's disease and have been shown to
occur in scrapie (62). Serotonin also has been shown to be
altered in Alzheimer's disease (5) and scrapie (82). Since
Alzheimer's disease and scrapie appear to share dysfunctions
in their neurotransmitters, elucidation of the role of specific
transmitters in Alzheimer's disease and CJD is important to
2determine if these are specific defects or if they are part of a
global effect of a related dementing process.
Creutzfeldt-Jakob Disease is known to produce severe
membranes alterations. Thus via direct disruption of integral
receptors and/or associated second messesger systems, changes
in the adenylate cyclase system may be manifest. Preliminary
studies investigating the functional capacity of membrane
adenylate cyclase in CJD showed an increased interaction of
adenylate cyclase regulatory subunits in CJD, resulting in an
increased cyclase activity in basal ganglia and hippocampal
membranes from guinea pigs infected with CJD as compared to
normal membranes (79). The integrity of the adenylate cyclase
system in CJD therefore appeared to be intact despite
pathological changes at the synaptic and membrane level. We
attempted to further characterize the alterations in adenylate
cyclase from neuronal tissue in Creutzfeldt-Jakob disease.
APPENDIX A
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Epidemiological studies indicate that between 2 and 4
million persons in the United States are currently afflicted with
a nonreversible dementia (5). The National Center for Health
Statistics estimates that by the year 2000 there will be 6.7
million people 85 years and older with the fastest growing
segment of the population those age 75 years and older (44).
The rapid growth of the elderly population at risk for
dementing disorders predicts a significant burden on our
society unless ways are discovered to prevent and treat this
"silent epidemic" of the next century. The most common
nonreversible dementia is neuronal degeneration of the
Alzheimer type occuring in more than one half the cases that
come to autopsy.
A small subset of human dementias, originally classified
with degenerative dementing illnesses of the Alzheimer type
are caused by infectious unconventional agents. Similarities
exist between Alzheimer's disease (AD) and the slow virus
group of dementing illnesses including Creutzfeldt-Jakob
Disease (CJD). Both show a similar average age of onset: AD:
67years with a range of 40-89 years, CJD: 60 years with a
range of 35-84 years. Familial cases constitute 10-15% of both
AD and CJD cases with an apparent autosomal dominant
inheritance. In an analysis of 73 families with CJD and 52
families with AD, four families were found in which one
member had pathologically confirmed CJD and at least two
members with AD. (61).
Creutzfeldt-Jakob Disease has an incidence of 1-2 per
million per year worldwide. Kuru, a disease limited to a region
of New Guinea has been shown to be transmitted by ritual
cannabilism (22) and has been eradicated with the termination
of this practice. A naturally occuring transmissible disease of
sheep (Scrapie) is also caused by a similar unconventional
4agent. All of these diseases share common pathological
(spongiform) changes in the CNS, have been shown to be
transmissible and lack an immune response to the infection.
This class of infectious agents is still not well characterized, but
notably these "viral" agents are small and resistant to a variety
of physical and chemical treatments.
In 1959 William Hadlow noticed histological similarities
between scrapie and the then newly described kuru. Kuru was
subsequently transmitted to nonhuman primates by Gajdusek
et al. (22). Histologic observations by Klatzo, Gajdusek and
Zigas further documented the common pathological features in
kuru and Creutzfeldt-Jakob disease. Subsequent transmission
of CJD to apes by Gibbs et al. (23) and to guinea pigs by
Manuelidis (51) further solidified the relationships between
these diseases.
CJD is a progressive neurological disorder characterized
by dementia, spongiform changes in the CNS and relatively
rapid decline to death (1-2 year clinical phase). In humans,
symptoms occur insidiously and their onset is difficult to date.
Initially the patient exhibits vague symptoms such as:
depression, anxiety, irritability followed by degrees of
confusion, memory defects and progressive dementia
accompanied by signs of upper and lower motor neuron
disturbance and myoclonus. In terminal stages the patient
becomes mute, rigid and unresponsive followed by coma and
death. The clinical phase ranges between 1-120 months with
the mean course about 10 months. EEG shows a characteristic
pattern of periodic bursts of sharp waves on a diffuse slow
backround (42).
The natural mode of transmission is still unknown. The
incubation among familial cases is postulated to be from 10-40
years. In iatrogenic transmissions (via corneal transplant (19)
ind depth electrodes (3), incubation time ranged from 18-30
months. There is evidence against maternal transmission in
experimental disease in rodents and primates (1,54). Viremia
of both guinea pig and man has been demonstrated by
5transmission of CJD from buffy coat preparations (52,53).
Further studies indicated that viral replication may take place
in lymphocyte populations (45). In animals, infectivity appears
in the spleen several weeks before high levels are apparent in
the brain.
About 65% of cases show some evidence of cortical
atrophy in CJD, mostly in the frontal lobes. The most
pronounced microscopic features are spongiform changes,
neuronal degeneration and astrocytic changes without
significant inflammatory infiltrates. The lesions are almost
exclusively in the gray matter although a Japanese varient has
been described with lesions in the white matter (65). The
majority of lesions occur in the cerebral cortex although there
is great variation between patients, and other regions have
been noted to be involved including basal ganglia, thalamus,
cerebellum, dentate nucleus, brainstem nuclei. Some of these
variants may be due to different (variant) isolates of the
infectious agent. Isolation of a variety of strains of the scrapie
agent, including those producing amyloid-like plaques, has
been accomplished using inbred mice with different alleles of
the '.scrapie incubation" gene ("SINC") that contols incubation
time (16,93).
Spongiform changes consist of small, well delineated
vacuoles scattered throughout the neuropil. They are most
often seen in dendrites and in the neuropil. The degree of
vacuolization is variable in different patients. Increased
numbers of astrocytes may be present. Inoculated animals
show essentially the same general histologic changes as seen in
human material. Electron microscopy demonstrates a decrease
in the number and organization of organelles in the perikarya
of neurons and astrocytes (43). Occasional vacuolar
membranous structures may be found in the perikarya.
Neuronal processes exhibit swellings with clearing of the
matrix These changes occur in both dendrites and axons as
well as in astrocytes. Large vacuoles seen under light
microscopy appear to be formed by progressive coalescing of
6adjacent swollen processes. Both neurons and astrocytes show
increased numbers of lysosomal structures.
It has been proposed (50), that some cases of Alzheimers
disease may also be caused by an unconventional agent.
However, thus far Alzheimers disease has not been shown to be
transmissible and there are no animal models directly derived
from this disease. Because the transmissible encephalopathies,
especially CJD share some similarities in clinical picture,
pathology and epidemiology, experimental CJD models are
useful for the study dementias of unknown etiology. With such
models the course of these degenerating dementias can be
followed from beginning to end. The identification of specific
disease mechanisms may shed light on potential common
pathway in all progressive dementias.
To date the CJD agent has not been identified. The agent
has been found in high titers in synaptosome enriched
membranes and is thought to be bound and/or sequestered
within the membranes at late stages of the disease (56).
Membrane disrubting detergents (Sarkosyl, NP-40, Triton X-
100) partially solubilize infectivity from synaptosomal
membranes (60). In both CJD and scrapie but not in normal
brain two components have been identified in the infectious
fractions. One is a protein component described as a
proteinase-K-resistant 27 to 30 kd gel band known as
"protease resistant" protein PrP27-30, or prion protein (76). In
CJD a 35 kd glycoprotein band (not digested with proteases)
that cross reacts with anti-scrapie PrP 27-30 antibodies have
also been identified (60). Although not visible in fractions
from normal brain, this 35 kd protein (or prion protein) has
been identified in normal homogenates (69). The cDNA of this
protein has been sequenced and corresponds to a normal
genomic DNA sequence that is transcribed as mRNA equally in
both normal and scrapie brain (9). This protein, when isolated
with SDS, shows no significant infectivity (57). Two theories
exist concerning the role of this protein in infectivity. One
group considers this protein itself is the infectious agent while
7two other groups postulate that this protein may represent a
marker or pathological product that co-sediments with
infectivity in many cases of CJD and scrapie. Studies of humans
have shown about 1/3 of cases fail to detect this protein (7).
The second component found in CJD and scrapie infectious
fractions has been termed SAF (scrapie-associated fibrils)(63).
SAF fibrils have a similar structure to (3amyloid of Alzheimers
disease but they are constituted by distinct peptides. SAF have
not been found in uninfected brain tissue (64). Although these
structures are present in purified infectious fractions, there
have been reports of infectious scrapie fractions with no SAF
present (77), although this may be a difference in terminology.
SAF and prion protein appear to be constituted by the
proteolytic cleavage products of Gp 34 (90). To date, no agent,
non host molecules of any sort have been detected in CJD or
scrapie .
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CNS neurons often have more than a thousand synaptic
inputs, many of these involve different neurotransmitters.
Signals presented at various sites and times are integrated by
converting them into the common intracellular languge of cyclic
nucleotides or calcium ions which are the most common second
messengers. Thus, integration of certain extracellular signals
can be achieved by changing intracellular levels of cyclic
nucleotides which serve as their second messengers. While
cyclic nucleotide systems occur in both neurons and glial cell
types, the specific activity of these enzymes is generally higher
in neuronal cell or in neuronally derived cell lines (101).
The composition and interactions of the adenylate cyclase
components within the plasma membrane of each cell type
varies and is subject to regulation of gene expression. Under
ordinary conditions it appears that receptor molecules and
nucleotide binding proteins are in excess over catalytic units of
the adenylate cyclase system. Occupancy of a receptor with an
agonist increases the probability of a coupling of the agonist
occupied receptor to the adenylate cyclase catalytic unit. This
reaction involves the mechanism described below. Receptors
are either stimulatory or inhibitory and are specific for the
hormone. The number of each receptor varies with cell type,
cell age, developmental status as well as hormonal and drug-
induced variations. Some of the hormones/transmitters
influencing the adenylate cyclase system include the following:
Stimulatory Inhibitory
Glucagon Opioids
Vasopressin Acetycholine
Epinephrine (P) Epinephrine (cc2)
Dopamine (D2) Dopamine (Di)
LHfSH.TSH Adenosine
VIP.ACT
Adenylate cyclase (AC) is a plasma membrane bound
enzyme system which functions as a "second messenger" to
catalyze the synthesis of cyclic AMP from ATP on the
cytoplasmic side of the membrane (Figure 11). In the CNS,
second messenger systems are integral components of cellular
functions which include phosphorylation of proteins important
for neurotransmitter effects, and cellular differentiation. The
synthesized cyclic AMP functions as an intracellular mediator
by virtue of its intracellular concentration, which can change 5-
fold upon hormonal or other external membrane stimulation.
The normal intracellular concentration of cAMP (<lu.M) is in
dynamic equilibrium and is influenced by two components:
a)stimulation of AC (which will increase the intracellular
concentration) and ^phosphodiesterases which hydrolyze
cAMP to 5'-AMP thereby decreasing the concentration of cAMP
intracellularly.
Receptors on the surface of the cell membrane activated
by hormones or other extracellular molecules do not activate
AC directly. Integral membrane proteins which binds GTP on
its cytoplasmic surface, couple the two together. These
proteins, called N proteins (or G proteins) were first suggested
by the requirement of GTP for hormonal activation of cyclase
(81). Addition of a hormone or other appropriate extracellular
binding molecule to the receptor of an adenylate cyclase
system results in three consequences: a)stimulation of the GTP-
mediated activation of the system, b)stimulation of the GTPase
activity of Ns (s indicates a stimulatory N protein, i indicates an
inhibitory N protein, see below) and c)stimulation of guanine
10
nucleotide release and/or exchange. The hormone-receptor
complex accelerates the activation of GTP-Ns by increasing the
affinity of Ns for Mg. By increasing the affinity for Mg, the
complex becomes fully saturated by Mg at physiologic
concentration of Mg, instead of requiring the higher
concentration needed without hormonal stimulation.
Inhibitory hormones will not change the affinity of Ni-GTP for
Mg, as this complex has a high affinity before interaction with
the hormone.
The hormone receptor complex has sufficient affinity for
the GDP-N complex that it drives their interaction and
promotes dissociation of GDP. This allows a subunit of N, a, to
bind GTP and become active. When GTP binds, the hormone
receptor complex dissociates. The GTP-N is then free to become
activated by its increased affinity for Mg (in the case of Ns)
followed by dissociate into sub-units (Figure 12).
N proteins in the membrane are activated upon binding
of guanine nucleotides. GTP or non hydrolyzable analogues of
GTP such as Gpp[NH]p and GTPyS are used in vitro to assess N
protein activation of cAMP in membrane preparations.
Magnesium concentration also influences adenylate cyclase
activity (see below).
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FIGURE 11: Theoretical model for adenylate cyclase system (41). AC
represents the catalytic unit of adenylate cyclase. Stimulation via stimulatory
hormones or other membrane targeting molecules enhances adenylate cyclase
activity by binding via receptor to Ns (+) along with GTP and increases
intracellular levels of cAMP. Cyclic AMP then activates specific kinases causing
phosphorylation of protein(s). Inhibitory hormones act through Ni to either
directly inhibit the catalytic unit (-) or to decrease Ns activation of the catalytic
unit (-).
There are many classes of N proteins. A stimulatory N
protein (Ns) activates cyclase and increases intracellular cAMP,
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an inhibitory N protein (Ni) has a direct effect on cyclase
decreasing the amount of cAMP produced, and also feeds back
upon Ns decreasing the stimulatory action of that N protein
(Figure 11). A third N protein (Nt) stimulates retinal cGMP
phosphodiesterase. N proteins also stimulate phosphoinositide
hydrolysis, and by this mechanism regulate intracellular
calcium (11) which is important in neuronal function. N
proteins have also been shown to regulate ion channels (32,73).
The elucidation of specific N proteins with stimulatory or
inhibitory functions was made possible by assays that purified
N proteins (68) and by the study of cells that lack specific N
proteins (i.e. eye" varients of S49 lymphoma cells that lack
stimulatory N proteins) (36). In addition, the capacity of
certain bacterial toxins to ADP-ribosylate specific N proteins
was discovered for cholera toxin (8,24) and pertussis toxin
(38,39) which proved useful in further characterization of N
proteins. Much of the basic understanding of the AC system
has come from studies on purified cyclase components.
Although there is good evidence that these findings hold true
in more complex systems (i.e. tissue membranes) the fact that
animal tissues contain many membrane components other than
the adenylate cyclase system, additional components in vivo
may influence the adenylate cyclase system.
N proteins are characterized by shared actions (25). First
both GTP and an appropriate hormone for the specific receptor
are required to initiate a response. Second, the response can
be provoked independently of the receptor by inclusion of
nonhydrolyzable analogues of GTP (Gpp[NH]p or GTPyS) in in
vitro studies. Third, there is negative feedback regulation
between the binding of a hormone to a N-linked membrane
receptor and the binding of guanine nucleotide to a N protein.
Fourth, cholera toxin and/or pertussis toxin have characteristic
effects on the functions of known N proteins.
The three well characterized N proteins (Ns,Ni,Nt) are
close structural homologs (68). All appear to have a a-(3-y
subunit structure. The a subunits contain a single high-affinity
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binding site for guanine nucleotides. In addition, the a
subunits are specific substrates for bacterial toxin catalyzed
ADP-ribosylation. For example cholera toxin activates Nscc
increasing intracellular cAMP and pertussis toxin acts on Nia to
yield a decrease in intracellular cAMP. The a subunits of N
proteins differ in molecular weight [Ns = 45 or 52kd, Ni = 41kd,
Nt = 39kd]. p subunits of all three N proteins however are very
similiar [35kd]. These polypeptides are functionally
interchangable and their amino acid compositions and peptide
maps are indistinguishable (91). The third subunit y is also
similar for all three N proteins [5-10kd]. Not much is known
about the y subunit which is tightly associated with p. p and y
dissociate together as a complex from Na in the presence of
activating hormones and like the P subunit are functionally
interchangable (Figure 12).
Stimulation of the catalytic unit of adenylate cyclase by
Ns requires the interaction of this catalytic unit along with the
activated guanine nucleotide-Ns subunit to form guanine
nucleotide-Nscc. The rate of activation of the coupling is
dependent upon the concentration of Mg ion. Activation of
cyclase is comparitively slow at physiologic concentrations of
Mg (0.5mM) and is accelerated (4-5 fold) when the Mg
concentration is increased (>10 fold). Rates of activation vary
according to the guanine nucleotide used. Nonhydrolyzable
Gpp[NH]p in vitro shows a slower activation than GTP. Studies
on cyclase activation have shown Gpp[NH]p to take twice as
long as GTP to reach maximal cAMP production (4).
Studies on the activation of biochemically purified Ns in
the presence of non-hydrolyzable guanine nucloetides show
the following: guanine nucleotide first interacts reversibly with
N, then the guanine nucleotide-Napy complex isomerizes in a
Mg dependent manner to give a complex in which the guanine
nucleotide does not dissociate. Finally the complex undergoes a
temperature-dependent subunit dissociation reaction to give a
Na-G complex and a NPy complex (12). All these reactions are
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reversible. Subunits reassociate on cooling and the guanine
nucleotide dissociates on removal of Mg (Figure 12).
GTP
GDP
Conformations
••-•-^P Inactive
ET"? Active
FIGURE 12. Regulatory cycle of N proteins (Ni or Ns) as it may occur under
the influence of GTP and Mg (44). The cycle is divided into four steps:
1 Association of GTP 2)activation of N and subsequent dissociation of N into Na*
and NfJy. 3)hydrolysis of GTP and deactivation of N 4)dissociation of GDP. The
undissociated a*-GTP|jy_Mg and the dissociated ot*-GTP are represented as active
GTPases as it is not known which form of the N protein hydrolyzes the GTP. This
cycle can represent Ns and/or Ni. Mg is present and drives the activation in steps
1 and 2.
The apparent Km of Ns for guanine nucleotides is in the
order of 10"^M. Since the intracellular concentration of GTP is
approximately 10'^M, guanine nucleotide is in excess and Ns is
always saturated. Under physiologic conditions, and in the
absence of hormonal stimulation, Ns does not fully stimulate
the AC system because Ns itself catalyzes GTP (GTPase) and
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therefore metabolizes its stimulatory form. Furthermore, the
Km for Mg is 5-10mM which is >10 fold higher than the
intracellular concentration of 0.5mM. Therefore under (non-
hormonal) stimulated physiologic conditions, the concentration
of Mg is too low to more than slowly activate Ns.
Magnesium shifts the equilibrium of the reaction to favor
activation of the N protein in the presence of GTP with
consequent stimulation by Ns (Figure 12). The rate of
dissociation of Gpp[NH]p from Ncc is slow. However Py increases
Gpp[NH]p or GDP rate of dissociation by about three fold (29).
Therefore high concentrations of Mg enhance subunit
dissociation to yield an extremely stable endproduct Na-
Gpp[NH]p-Mg.
In vitro regulators of activity include non-hydrolyzable
GTP analogs which are modified by substituting
imidodiphosphate (Gpp[NH]p) for the pyrophosphate of GTP, or
by substituting thiophosphate (GTPyS) for the phosphate of
GTP. These analogs are useful because they retain their ability
to interact with GTP-specific sites(and compete with GTP for
these sites). They also are relatively resistant to hydrolysis.
The latter feature depends on the modified phosphate
contained in these analogs. Such GTP analogs are
quantitatively more effective than GTP in stimulating cyclase
activity. Although GTP without hormone generally is not very
effective in stimulating adenylate cyclase (see above),
nonhydrolyzable analogs are often quite effective. Also,
analogs plus hormone generally give higher rates of cyclase
activity than hormone plus GTP. Nonhydrolyzable analogs lead
to a qualitatively different state of "persistent" activation
causing an apparent increase in agonist potency for enzyme
acitvation. In summary nonhydrolyzable analogs allow for
stimulation of the adenylate cyclase system without the use of
hormones. Since the hormone-receptor complex alters the
adenylate cyclase system, use of these analogs allows
investigation of the intrinsic adenylate cyclase stimulatory
system.
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Ni like Ns is a GTPase. The two differ in their affinity for
Mg. While the affinity of Ns for Mg is low, that of Ni is high.
Therefore at physiological conditions, Ni is saturated not only
by guanine nucleotides but also by Mg. Ni can act on Ns (Figure
11). The inhibition of adenylate cyclase, via inhibition of the
Nsa-catalytic unit complex arises from a local increase of Py
complex (from stimulation of Ni by GTP and Mg, and by the
concomitant subunit dissociation reaction) (4). In addition to
inhibition via this indirect mechanism there is evidence for a
direct effect of Nice on the cAMP catalytic unit. This is
illustrated in studies showing that Ni is active in reducing AC
activity in Ns-deficient systems such as in the eye" varient of
the S49 lymphoma cells (30,36). These two mechanisms of
inhibition are non-competitive. The direct mode of inhibition is
not due to displacement of Nsoc from a common site on the
catalytic unit.
Under conditions with no hormonal influence, these two
systems (Ns, Ni) continuously cycle giving rise to steady state
levels of active Ns and Ni as well as basal rates of GTP
hydrolysis. Therefore whenever GTP (or GTP analog) effect on
AC is measured, the activity measured is a balance of both the
amount of activated Ns (stimulating AC) and activated Ni
(inhibiting Ns and AC) (4).
Several other chemicals are useful for investigating
specific features of the adenylate cyclase system. Forskolin, a
diterpine, activates adenylate cyclase systems. Although its
exact mode of action is unknown, studies indicate that it
functions by interacting with the catalytic unit of adenylate
cyclase causing an increase in cAMP. In addition, the
expression of its effect is dependent on, and/or affected by,
additional factors and/or compounds including Ns (10). In.
vitro forskolin stimulates the complete adenylate cyclase
system many more times than other stimulators such as
Gpp[NH]p or NaFl (3 fold the stimulation by Gpp[NH]p alone
(89) and thus can be used to determine maximal cyclase
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response of a system. In addition hormones acting through Ni
are better seen in a forskolin-stimulated assay than in an
unaffected system (4,89).
Mangenese activates the catalytic unit of the AC system.
Under known assay conditions it reflects activity of the
catalytic moiety of adenylate cyclase independent of the
guanine nucleotide-Ns complex. Activity stimulated by Mn^ +
can therefore be used to evaluate the relative quantity of
intrinsic AC activity in different membrane preparations.
The lateral mobility of the AC components within the
membrane is necessary for the formation of complexes that
lead to activation of the enzyme and production of cAMP.
Lateral mobility may be influenced by integral membrane
proteins kept in place by both submembranous structures
(spectrin) and cytoskeletal proteins. The mobility of adenylate
cyclase components is also restricted by membrane lipids.
Increases in membrane fluidity augment enzyme activity
whereas activity is reduced when membranes become more
rigid.
One membrane fluidizer is ethanol. Ethanol exerts its
physiological effects by interacting with the lipid components
of cellular membranes. Numerous studies have demonstrated
that ethanol and other alcohols disrupt or fluidize the lipid
structure of membranes. Ethanol appears to increase the rate
of activation of cyclase by guanine nucleotides and
concomitantly increase the affinity of the system for
magnesium. The effect of ethanol can vary in different regions
of the brain (98); thus it has been suggested that ethanol may
have selective effects on different receptor-coupled adenylate
cyclase systems.
Colchicine and vinblastin, antimicrotubule drugs, have
also been reported to potentiate hormone-stimulated cAMP
production in a variety of cell systems. Studies have shown
these compounds release a 42kd GTP-binding protein from
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synaptic plasma membranes along with loss of G-unit activity
(80). Loss of these adenylate cyclase components after
colchicine treatment suggests tubulin can modify the coupling
process within the adenylate cyclase system.
Amphotericin B is a polyene that binds sterols.
Cholesterol is a major lipid component of the plasma membrane
that interacts with phospholipids in the membrane to suppress
non-specific leakage of polar substances across the bilayer and
modulates bilayer fluidity. Elevation of cholesterol
concentrations in plasma membranes has been shown to lead to
an inhibition in adenylate cyclase activity (102).
Amphotericin B by binding cholesterol results in
increased adenylate cyclase activity. Interestingly, scrapie
infected animals treated with amphotericin B extended their
incubation times (i.e. decrease the agent replication) even after
intra-cerebral inoculation of the agent (75). Because of this
effect in scrapie, and its role in influencing adenylate cyclase,
the possibility exists that amphotericin B may be shown to
reverse the CJD alterations in cyclase.
19
MATERIALS AND METHODS
Animals:
Tissue was obtained from a serially passaged models of
CJD. Guinea pigs were Hartley strain from Charles River
Laboratory and hamsters were LVG strain also from Charles
River. Both species were inoculated intracerebrally as
weanlings with 10% homogenate of infected brain tissue in
normal saline. Inoculations were made into the right side of
the cortex. Animals were sacrificed when showing typical signs
of CJD. For guinea pigs this was approximately 20 weeks while
for hamsters it was closer to 18 weeks.
Animals were sacrificed and brains removed rapidly.
The brains were disected on ice into regions: basal ganglia,
cortex (occipital-parietal and frontal), hippocampus and
cerebellum. Each region was placed in a cold Dounce
homogenizer with a 10 fold volume of Buffer A*, and
homongenized 15 strokes with a loose fitting (B) size pestle.
The homogenate was then poured into a sealed polypropelene
tube and centrifuged in a Sorval centrifuge HB-4 rotor at 1500
rpm (365g)for 15 minutes. The supernatant was poured off
into another tube and spun again at 9500 rpm (14,600g) for 20
minutes. Supernatants from this last spin were discarded and
the pellet vortexed up in 0.5 to 1ml of the buffer and frozen in
liquid nitrogen. Small samples (20u.l) were taken before
freezing for protein assay. These frozen pellets were composed
of synaptosome-enriched membrane fractions. Normal control
animals at approximately the same age as the CJD infected
animals were prepared in the same way.
*Buffer A: KC1 800mM, NaCl 150mM, Spermine 1.5mM,
Spermidine 5mM, Tris Acetate 150mM, EDTA 2mM, EGTA
0.5mM, 2-Mercaptoethanol 15mM, Sucrose 0.1 IM, PMSF
0.5mM.
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Adenylate Cyclase Assay:
The AC assay used was according to the method of
Salomon (86) with the following buffers:.Membrane Buffer:
Hepes (GIBCO) 25mM, Dithiothreitol (DTT) (Sigma) ImM, PMSF
(Sigma) 0.75mM, MgCl2 0.1-lmM. Pre-Incubation Buffer: Hepes
(GIBCO) 25mM, NaCl 60mM, DTT (Sigma) ImM, EGTA 0.5mM,
MgCl2 l-5mM. Incubation Buffer: ATP (Sigma). ImM, IBMX
(Sigma) 0.5mM, NaCl 60mM, cAMP (Sigma) 0.05mM, EGTA
(Sigma) 0.5mM, Hepes (GIBCO) 25mM, DTT (Sigma) ImM,
Creatine Phosphokinase (Sigma) 0.14mg/ml, Creatine Kinase
(Sigma) 0.5mg/ml, Myo-Kinase (Sigma) 15U/ml, Adenosine
Deaminase (Sigma) lU/ml, BSA 0.25mg/ml, MgCl2 l-5mM, a32P
ATP 500,000 cpm/tube.(New England Nuclear) Stop Solution:
SDS 2%, ATP 45mM.
Guanine Nucleotides: Gpp[NH]p (Boeringer Mannheim) ,
and GTP (Sigma) were added at similar dilutions (10"^-10"^M).
Neurotransmitters tested included Dopamine(DA) (Sigma) 10"
6-10"8M in 0.1% ascorbic acid, Serotonin(5HT) (Sigma) 10"6-
10~8in 0.1% ascorbic acid, D-Ala2-Met5-Enkephalinamide
(Sigma) 10"^M, Vasoactive Intestinal Peptide(VIP) (gift from
Dr. B. Bunney) 5xl0"^M. The fluidizers Forskolin (Sigma) 10"
2M, Ethanol 500mM(3%), Colchicine (Sigma) 10"7M,
Amphotericin B (Sigma) 10'^M were also tested. (All additive
are at their final concentrations.)
Procedure: Tubes were prepared in triplicate (12x75 mM
borosilicate glass) and placed on ice. Pre-incubation
components were added to a total final volume of 65X/tube as
follows: 25u.l of Pre-Incubation Buffer , 10(il of guanine
nucleotides (GTP or Gpp[NH]p) , lOuJ of fluidizers (Etoh, Amp B,
Colchicine), neurotransmitters ( dopamine, 5HT etc.), or
forskolin, and adjusted with distilled water up to the final
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volume. Guanine nucleotides and buffer were used in virtually
all tubes, with the other components added in separate
experiments.
Membranes were thawed and the pellet was washed in
approximately 1ml of Membrane Buffer, then centrifuged at
ll,000rpm in an Eppendorf refrigerated centrifuge. The pellet
was resuspended in Membrane Buffer to a final concentration
of 5-20 (xg of protein/tube. Protein determinations were
completed on samples of membranes taken before freezing.
Membranes (25|il) were added to the tubes containing pre
incubation buffer. Tubes were pre-incubated at 30° C for 10
minutes. After 10 minutes, 10|il of Incubation Buffer was
added and the reaction continued at 30°C for another 10
minutes (5 minutes of incubation was used if inhibitory
reactions were to be enhanced). The reaction was terminated
with lOOul of Stop Solution. 50^1 of 3H cAMP (10,000
cpm/tube) were added to each tube followed by 1ml of water.
These preparations were then chromatographed on columns.
Chromatography columns for assay of cAMP were
prepared according to the method of Salomon (86). Dowex AG
50W-X4 (200-400 mesh) columns were washed with 20ml of
de-ionized water prior to each use. Alumina columns were
washed with 10ml of 0.1M Imidazole buffer before each use.
Reaction tubes were inverted over the columns and allowed to
drain. This was followed by washes with water (two 1.25ml
washes that were allowed to drain and one 5ml wash after the
Dowex columns were stacked on top of the Alumina). The
Dowex columns were removed, scintillation vials were placed
under the Alumina columns and each column was washed with
5.5ml of 0.1M Imidazole buffer. Sixteen milliliters of
scintillation fluid (Optifluor) was added to each vial and they
were counted on a combined ^H and 3 2p channel for 5
minutes/vial. The tritium window was set at 1-400 and the
32p at 415-1000. The Dowex columns were recharged with
2ml of IN HC1 before storing.
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All results were calculated and corrected for protein.
Protein values were based on analysis of the membrane
suspensions after they were prepared for the assay. Results
are expressed in cAMP pM/mg protein/minute of reaction.
RESULTS
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Initial experiments showed an increase in coupling of
stimulatory subunits (Ns) in CJD membranes (79). Using
Gpp[NH]p to study the Ns dependent activation of adenylate
cyclase, guinea pig basal ganglia membranes activated cyclase
66%(±17,S.D.) greater than normal membranes. In subsequent
experiments with different samples, synaptosomal membranes
from CJD guinea pig basal ganglia similarly gave a greater fold
Gpp[NH]p stimulated cyclase than did membranes from normal
animals. Synaptosomal membranes from CJD and control
guinea pig basal ganglia were incubated with Gpp[NH]p under
stimulatory conditions (high Magnesium) with no pre
incubation (Figure 1).
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FIGURE 1: CJD and normal membranes were incubated for 10 minutes at
30°C in Incubation buffer (see methods) containing 4mM MgCl2, Gpp[NH]p and ImM
EGTA. No pre-incubation was used. Remainder of protocol was as per methods.
24
Stimulation of CJD membranes with Gpp[NHlp shows a
greater activation in cyclase (cAMP) as compared to uninfected
membranes. CJD tissues gave a Gpp[NH]p stimulation of 2.5
fold. Basal activity was 354pM of cAMP/mg protein/minute.
(Basal activity refers to the amount of cAMP generated from
membranes in a tube without addition of guanine nucleotides,
hormones or other modifiers of activity. The fold stimulation
was determined at Gpp[NH]p concentrations of 10'^M.) The
cAMP/mg protein/minute increased steadily to a maximal
value of 872. In contrast normal tissues yielded only a 1.1 fold
stimulation over basal levels with Gpp[NH]p. Unlike the CJD
membranes, the normal gave a higher basal activity of
868pM/mg/min. and did not steadily increase with rising
Gpp[NH]p concentration but instead decreased to
697pM/mg/min at a Gpp[NH]p concentration of 10"7M before
again rising to a peak of 984pM/mg/min. (Figure 2)
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FIGURE 2: Guinea pig basal ganglia membranes were incubated as above in
Incubation buffer containing 9mM MgCl2 and ImM EGTA, with Gpp[NH]p ranging
from 10"9 to 10"4M.
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In studies utilizing a more extensive range of Gpp[NHlp
concentrations, CJD membranes gave a stimulation of 2.0 fold.
The basal activity of 565pM/mg/min. remained stable up to a
Gpp[NH]p concentration of 10"7M. Activity then steadily
increased to a maximum of 1 146pM/mg/min. Normal
membranes, with a stimulation of 1.4 fold (compared to basal
[no Gpp[NH]p]), showed the same curve of activity as seen in
figure 1. Basal activity of 1463pM/mg/min remained
unchanged at the Gpp[NHlp concentration of 10~9M then
decreased to a low of 1 lOOpM/mg/min at a Gpp[NH]p
concentration of 10"^M, before steadily rising to a maximum of
1810pM/mg/min.
Figures 1 and 2 depict three pertinent differences
between the CJD and normal membranes: a) normal
membranes show a dip in activity at low Gpp[NH]p
concentrations while CJD activity remains stable; b) CJD shows
a lower total amount of cAMP/mg protein produced throughout
the curve, and c) CJD continues to show a higher fold
stimulation compared to basal (no Gpp[NH]p) than does normal.
The higher fold stimulation of CJD membranes supports the
earlier evidence suggesting that coupling of the stimulatory
subunit (Ns) is greater in CJD than in normal membranes; the
portion of decreased activity in the normal curve may suggest
that normal tissues contain an inhibitory component of their
cyclase system that is lacking in CJD. This inhibitory activity
appears to be specific for Gpp[NH]p concentrations between 10"
9 and 10"^M. This presumed lack of Ni in CJD was investigated
with inhibitory hormones (see pg.23-26). Variations in the
amount of intrinsic Ns-GTP present in the membranes however
could limit the maximal amount of activity and might account
for the differences seen between CJD and normal membranes in
the presence of Gpp[NH]p (Figure 2). Additionally, the in vivo
state of the receptor influenced by hormone, might also lead to
normal and CJD differences in the assay.
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In order to investigate another potential variability we
used manganese and forskolin to study maximal amounts of
stimulatable cyclase. Mangenese and forskolin are substances
which maximally stimulate cyclase (see Appendix B).
Comparison of maximal values between CJD and normal
membranes allowed us to determine if the amount of
stimulatable cyclase was the same in both normal and CJD
membranes, i.e. if steady state in vivo factors such as hormones
were responsible for the above differences.
Initial experiments with manganese showed stimulation
was equal in CJD and normal membranes (79). Repeat
experiments on cortex and basal ganglia in hamster and guinea
pig as well as hamster cerebellum and guinea pig cortex also
showed that in all of the above tissues, the fold stimulation by
Mn was equal in CJD and normal membranes. This finding
indicates that even with the membrane damage inflicted by the
CJD agent, the cAMP catalytic moiety of adenylate cyclase at
the very least remains intact and functional since stimulation
of the cyclase system by mangenese is a measure of the
catalytic activity of the system without the influence of Ns
components or hormones.
Forskolin stimulates cyclase by primarily acting directly
on the catalytic unit (as does Mn) but it also is thought to act
through other poorly described mechanisms, one of which is
through Ns. Experiments showed that in all of the above
tissues (except guinea pig basal ganglia), forskolin stimulation
(fold cAMP) was equal in CJD and normal membranes (data not
shown). Guinea pig basal ganglia was different in that CJD
membranes had a higher fold stimulation with forskolin than
did normal membranes (1.35 ± 0.10). Thus in general there
appears to be no difference in the catalytic moiety in CJD and
normal membranes, although in guinea pig basal ganglia there
is increased coupling of forskolin on Ns (leading to the
increased fold stimulation). This forskolin change may be due
to its other poorly understood effects on Ns.
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Since normal membranes showed a higher basal cyclase
activity than those of CJD (Figures 1 and 2), the initial (steady
state) activities of membranes were investigated by varying
conditions of pre-incubation. (Steady state refers to the
proposed state of membranes in vivo in a non-stimulated
state.) Pre-incubation of membranes (under standard
Gpp[NH]p concentrations) before addition of substrate should
allow the formation of a new steady state in vitro, independant
of the in vivo steady state. Changes in activity with varying
time of pre-incubation yielded information on the initial state
of the CJD and normal membranes in vivo.
Normal membranes without additions of guanine
nucleotides, show decreasing activity with increasing time of
pre-incubation (with the exception of the zero time point which
could be an inaccurate point.). CJD tissues in contrast show a
more stable but lower level of pre-incubation profile. With
increasing time of pre-incubation, the activation in normal
membranes decreases until it equals the CJD membranes at 20
minutes. The actual values of the basal cyclase after pre
incubation are very close in CJD and normal ( i.e. CJD = 4798 pM
cAMP/mg protein/minute, normal = 4703 pM/mg/min).
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FIGURE 3: Hamster basal ganglia membranes (CJD and control) were pre-
incubated in Pre-incubation buffer (see methods) containing 5mM MgCl2 ,and 10"
4M Gpp[NH]p for 0,5,10,15 and 20 minutes. This was followed by addition of
Incubation buffer for an additional of 10 minutes at 30°C. (The CJD 10 minute
point was not done under standard conditions.)
The overall impression from these experiments is that
with the same amount of cAMP catalytic subunit (and therefore
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the same quantity of stimulatable cyclase), normal tissues
appear to have more GTP bound Ns in their steady state than
do CJD membranes. A proposed mechanism would be for
normal membranes to have a greater amount of GTP-Ns
(activated complex, see Figure 12 in Appendix B) in the steady
state than in CJD. With increasing time of pre-incubation the
GTP will hydrolyze, and more of the inactive GDP-Ns form will
appear. Thus after 20 minutes of pre-incubation both CJD and
normal membranes will have the same amount of active (GTP-
Ns) and inactive (GDP-Ns) forms.
While pre-incubation under basal conditions (no
additives) gives some indication of the steady state of the
membranes, pre-incubation with Gpp[NH]p gives additional
information and helps further characterize the steady states.
Pre-incubation of CJD with Gpp[NH]p showed an increase in
stimulation over time. The Gpp[NHlp fold stimulation versus
time of pre-incubation showed that CJD has a more rapid rise of
Gpp[NHlp fold stimulation than normal. Furthermore in CJD
there is a plateau after 10 minutes of pre-incubation, while
normal membranes show a steady but slower rate of increase
(Figure 6). This difference is due to the increased GTP-Ns in
normal versus CJD membrane preparations.
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FIGURE 4: Plot of Gpp[NH]p fold stimulations verses pre-incubation. Data
is taken from the previous pre-incubation experiment on hamster basal ganglia
(see Figure 5). Since cAMP is initially higher in the normal at short pre
incubation times there is a shift to the right in the normal curve.
Thus in summary there appears to be more activated Ns
(Ns-GTP complex) in membranes prepared from normal
animals than in those prepared from CJD infected animals. This
yields a higher basal level of activity without pre-incubation
(Figure 1,2). In normal membranes the observed fall off in
pre-incubation activity appears to be secondary to hydrolysis
of GTP seen with increasing time of pre-incubation and more
inactive (Ns-GDP) and reflects the initial in vivo differences in
CJD and normal memranes. Further support for this comes
from Gpp[NH]p experiments where an increase in normal
membrane activity after a lag is a result of the conversion of
Ns-GDP to an unbound state during pre-incubation. Because of
the relative lack of basal activity in CJD, membranes appear
initially to be a predominately inactive steady state (Ns-GDP)
and therefore yield a rapid rise in cAMP with Gpp[NH]p.
Q.
X
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Addition of Gpp[NHlp may not only fill available guanine
nucleotide sites but perhaps enhance the affinity of Mg which
is also an integral component for Ns activation (see Appendix
B). Therefore in the steady state, CJD may be deficient in two
important stimulatory components viz. GTP and Mg. However
CJD membranes appear to retain their capacity to maximally
stimulate cyclase when these components are added.
Since the maximal fold difference in Gpp[NH]p stimulated
cyclase occured at 10 minutes (Figure 4), we used 10 minutes
for our standard pre-incubation time in further experiments.
Pre-incubation of 10 minutes results in approximately equal
basal levels indicating that both membranes are in a similar
activation state at this time. A parallel Gpp[NH]p dose
response, with a 10 minute pre-incubation, now show basal
levels of cAMP are equal in CJD and normal membranes (Figure
5).
In addition the normal membranes have lost their
inhibitory dip and demonstrate a steady rise of activity as the
concentration of Gpp[NH]p increases, most likely due to
rendering normal membrane Ns equivalent to that in CJD.
Notably even with equalization of basal levels, Gpp[NH]p fold
stimulation remains higher in CJD (by 48%) than in normal
membranes.
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FIGURE 5: Guinea Pig basal ganglia membranes were pre-incubated in Pre
incubation Buffer with 5mM MgCl2 and Gpp[NH]p for 10 minutes at 30°C.
Incubation Buffer was added and incubation continued for 10 minutes more at the
same temperature. The reaction was terminated and continued as per methods.
Bars indicate standard deviation.
Pathological changes in CJD infected brain vary from
region to region, and regional involvement varies with species
and agent isolate. We used one isolate to characterize
adenylate cyclase changes in two species. In hamsters cortical
tissues show vacuolization at 14 weeks of incubation, and there
are only minimal basal ganglia changes at terminal disease in
hamsters. The cerebellum also shows little evidence of
vacuolar change. Guinea pigs show considerably more
vacuolar changes in basal ganglia than hamsters when these
species are inoculated with the same agent isolate. Since there
is pathologic regional variation, Gpp[NHJp fold stimulation was
studied in different regions of brain.
As described above the Gpp[NHlp fold stimulation of
adenylate cyclase is higher in CJD than in normal membranes.
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In guinea pig basal ganglia and in hamster cortex membranes
this trend was clear and appears to reflect the predominant
region that is involved in each species. For example there is a
clear increase in CJD fold stimulation over that of normal in 5
out of 6 guinea pig basal ganglia experiments and in 4 out of 5
hamster cortex experiments, and these are statistically
significant.
Gpp[NH]p Fold Stimulation
Exp
l
2
3
4
5
6
Exp.
l
2
3
4
5
QD M
2.5 1.1
2.0 1.4
2.8 1.8
2.5 2.1
3.7 2.7
11 IA
2.7 ± 0.56 1.7 ±0.52
QD m
3.3 2.5
2.4 2.2
5.8 4.5
3.8 2.6
4,2 1A
4.0 ± 1.28 3.0 ±0.90
%C/D>Nl
56%
30% Guinea Pig
36% Basal Ganglia
16%
28%
49%
36% p=0.003
%CID>M
25%
9% Hamster
23% Cortex
32%
31%
24% p=0.012
TABLE 1: Summary of experiments investigating Gpp[NH]p stimulated
adenylate cyclase. Experiments include those with and without pre-incubation.
Results are expressed as fold stimulation and percentage increase in CJD versus
normal in paired experiments. The negative value in experiment 2 in hamster
cortex is likely due to inclusion of 2 brains from animals not showing clinical
signs (occassional animals receive an inadaquate inoculum). If this experiment is
omitted the p value is 0.004.
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Hamster basal ganglia and guinea pig cortex gave
inconsistant results (not shown) with Gpp[NH]p fold stimulation
larger in CJD than normal in half the experiments and
approximately equal in the other half. Since a smaller number
of experiments were done on these regions, the findings are
not as convincing as the two above. However they may relate
to the predominant regional targets in these species. Cerebellar
membranes showed no difference in Gpp[NHlp fold stimulation
between CJD and normal. This is consistant with the fact that
the cerebellum does not appear to be microscopically affected
in these animal models of CJD. Notably, cerebellum contains
>20 fold less infectivity than cortex at end stges of disease (59).
Since CJD disrupts neuronal membranes, alteration in
membrane fluidity and/or cytoskeletal structure was
considered as a possible explanation for the general increase in
adenylate cyclase stimulation seen in CJD as compared to
normal synaptosomal membranes.
Ethanol can interact with the lipid components of cellular
membranes and "fluidize" these components. Its effects on
membrane cyclase activity are well characterized
(31,48,94,100). Since interactions between various components
of the adenylate cyclase system take place within the lipid
milieu of the plasma membrane, ethanol may be expected to
affect these interactions by perturbing membrane lipids.
Likewise, CJD may similarly influence interactions between
adenylate cyclase components by disrupting the integral
structure or fluidity of membranes. Incubating membranes
with ethanol was used to determine if CJD membranes were
comparably fluidized: If there is preexisting fluidization of
membranes in CJD, one would expect to see an increase in
cAMP with ethanol in normal membranes but little or no effect
with ethanol in CJD, i.e. the membranes are maximally fluidized
in CJD. Membrane fluidity was evaluated by examining the
effect of ethanol on Gpp[NHlp dose response curves in parallel
in CJD and normal membranes.
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FIGURE 6: Guinea pig basal ganglia membranes were pre-incubated in Pre
incubation buffer containing 5mM MgCl2, Gpp[NH]p 10"^ to 10"^M, and ethanol
500mM (3%). Membranes were pre-incubated 10 minutes at 30°C, Incubation
buffer was added and membranes incubated for 10 additional minutes at the same
temperature. Reaction was terminated and assay completed as per methods.
Ethanol increased the slope of the Gpp[NH]p dose
response curve as well as the amount of cAMP (pM/mg/min)
generated in both CJD and normal membranes. The Gpp[NH]p
stimulation of cyclase in normal membranes by was 1.9 fold
but increased to 2.2 fold upon addition of ethanol. In CJD
Gpp[NH]p stimulation was 3 fold (greater than normal as
previously). With addition of ethanol, although the total
activity increased the fold stimulation was the same. In
contrast the fold stimulation with ethanol was increased in
normal membranes. The effect of ethanol on membranes in a
true basal state (i.e. no activity) should be negligible. The fact
that ethanol does affect the basal activity indicates that the
membranes had varing amounts of Ns-GTP available for the
■*■ NI Gpp
♦ NI Gp & Eto
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-o- Cj Gp & Etoh
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increasd coupling by ethanol. Data from other similar
experiments showed the same effect; that is Gpp[NHlp + ethanol
gave a higher fold stimulation than Gpp[NH]p alone in normal
membranes, while it had much less effect on the fold
stimulation in CJD membranes.
The difference in Fold Change
(Gpp[NH]p+Etoh I Gpp[NH]p)
Exp. Normal QD
l 1.15 1.00 Guinea Pig
2 1.13 0.96 Basal Ganglia
3 0.96 0.92
1 1.12 0.81 Hamster
2 1.30 1.18 Cortex
Average : 1.13 ± 0.12 0.97 ± 0.13 p = 0.023
TABLE 2: Membranes were incubated in the presence of Gpp[NH]p ± ethanol
(500mM). Values are expressed as the difference in the fold stimulation between
Gpp[NH]p + ethanol and Gpp[NH]p alone (basal). The p value of all 5 experiments =
0.023 which is significant.
The data shown above reflects the fold differences
between Gpp[NH]p + ethanol and Gpp[NH]p alone. Similar
results are seen in plots of the cAMP generated (Figure 7).
Since ethanol does not increase the fold stimulation of
Gpp[NH]p in CJD to the same extent as it does in normal
membranes, the CJD agent and ethanol may be altering the
membranes in a similar fashion.
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FIGURE 7: Membranes were pre-incubated in Pre-incubation Buffer
containing 5mM MgCl2, Gpp[NH]p 10"^M, ± ethanol 500mM (3%). Membranes were
pre-incubated 10 minutes at 30°C, Incubation Buffer was added and membranes
were incubated for 10 additional minutes at the same temperature. The reaction
was terminated and the assay completed as per methods.
Notably the cortex of hamster CJD infected membranes
was more fluidized then basal ganglia. Hamster cortex shows
stimulation with ethanol in normal membranes but not in CJD,
as would be expected if the CJD membranes were already
fluidized. This suggests that fluidization is a major effect of CJD
(disease or agent) on hamster cortical tissue. In hamster basal
ganglia the lack of fluidization effects of ethanol were not
surprising as this tissue is less involved by disease.
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We also investigated other mechanisms that might lead to
the cyclase stimulation in CJD. Treatment of brain synaptic
membranes with colchicine or vinblastine and Gpp[NH]p results
in augmentation of adenylate cyclase activation (80) due to
disruption of tubulin within the plasma membrane. This leads
to increased coupling of the N protein and increased AC activity
(80). Membranes were incubated with colchicine in an effort to
investigate this mechanism in CJD.
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FIGURE 8: Guinea pig basal ganglia membranes were pre-incubated in Pre
incubation buffer containing 5mM MgCl2, ImM EGTA, Gpp[NH]p 10"^M and
colchicine 10"^M for 10 minutes at 30°C. Incubation buffer was added and
reaction was incubated for an additional 10 minutes at the same temperature.
Assay proceeded as per methods.
Colchicine appeared to have no effect on adenylate
cyclase with fold stimulations of Gpp[NHlp + colchicine equal to
that of Gpp[NH]p alone. Both CJD and normal membranes
incubated as above but without GppfNHlp (basal activity) gave
a 20% inhibition upon the addition of colchicine. It is possible
that colchicine altered the coupling of N proteins in these
H Basal
0 Gpp[NH]p
E3 Gpp+Colchcine
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membranes but in such a way as to inhibit rather than
stimulate adenylate cyclase activity, possibly by enhancing Ni
subunit dissociation over Ns. Addition of Gpp[NH]p may
overshadow this effect and give the overall result of no change
of cyclase stimulation with colchicine. Regardless of the
mechanism, both CJD and normal membranes respond to
colchicine in the same way. This suggests that disruption of
tubulin is not a factor in the mechanism of the observed CJD
alterations in adenylate cyclase activity.
Amphotericin B not only affects membrane fluidity by
binding cholesterol, but has also been shown to lengthen the
incubation period of scrapie in experimental animals (74). If
CJD affected membranes by binding cholesterol (as does
amphotericin B) one would expect to see an increase in
Gpp[NH]p stimulated cyclase in normal membranes while
visualizing a smaller effect in the CJD membranes that had
already been fluidized. Preliminary experiments on normal
hamster basal ganglia showed no effect of amphotericin B on
the Gpp[NHlp dose response curves. Therefore the adenylate
cyclase system in this system does not appear to be affected by
alterations of cholesterol in the membrane.
Previous studies in scrapie infected animals have shown
decreased levels of serotonin (5-HT) in whole brain
homogenates of mice and in peripheral blood of hamsters (82).
Behavioral aspects have been ascribed to 5-HT
supersensitivity, secondary to possible destruction of the 5-HT
nerve terminals (26). Earlier experiments with CJD guinea pig
basal ganglia were incubated with 10"6jVI Gpp[NH]p over a
range of 5-HT concentrations ranging 10"9 to 10"5jYI (79)..
In the present experiments guinea pig basal ganglia,
cortex and hamster cortex were incubated with Gpp[NHlp at a
range of concentrations and 5-HT (5xl0"5jyi) in an effort to
observe a supersensitivity response to the hormone in CJD
membranes. In all experiments CJD failed to show an increased
response to 5-HT over that of normal membranes. Stimulation
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of cyclase by transmitters was enhanced by keeping the Mg at
a relatively high concentration (5mM) thereby promoting Ns
saturation with the ion (Appendix B) for a constant baseline to
observe Ni effects. In addition to altering the Mg
concentration, the use of forskolin, especially in conjunction
with low Mg concentrations was used enhance visualization of
inhibitory neurotransmitter effects (4). None of our
experiments showed an increased sensitivity to 5-HT. The
failure to elicit a response to 5HT is possibly due to a low
number of 5-HT receptors in the membrane preparations of
these brain regions. Depletion of 5-HT in regions of CJD brain
would explain a part of the supersensitivity noted in other
studies as well as the behavioral characteristics seen in these
animals: increases in irritability, aggressiveness, activity and
sensitivity. Since other studies examined whole brain
preparations instead of specific brain regions, it is possible our
experiments contained too few 5-HT sensitive regions.
Dopamine (DA) both stimulates and inhibits the formation
of cAMP in the striatum (97). Stimulation of Dl receptor sites
enhances activity of adenylate cyclase, while stimulation of D2
receptors does not (40). Some D2 receptor populations when
stimulated cause inhibition of cyclase activity and reduction of
intracellular cAMP (15,20). Cells may contain Dl or D2
exclusively, or may contain both receptors that function
independently and have opposite effects on intracellular cAMP
levels (41). Dopaminergic neurons have modulatory influence
on the structures they innervate rather than any specific
intrinsic function (47).
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FIGURE 9: Membranes from guinea pig basal ganglia were pre-incubated for
10 minutes at 30°C in Pre-incubation buffer that contained ImM MgCl2 (to enhance
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inhibitory conditions), GTP 10"4M, dopamine 10"4M.or opiate(D-Ala2-Met5-
Enkephalinamide) at 10"5M. Forskolin was added to half of the tubes in a
concentration of 10"^M to further enhance the inhibitory effect of the hormones.
Incubation buffer was added and incubation continued for 10 minutes at the same
temperature. Error bars reflect S.D..
Guinea pig basal ganglia membranes were incubated with
dopamine under inhibitory and stimulatory conditions to
determine the response of the membranes to the dual effects of
dopamine. In addition, membranes were also incubated with
an opiate under inhibitory conditions to test the inhibitory
capacity of the membranes.
Addition of dopamine with GTP enhanced stimulation
over that of GTP alone: CJD=29% and normal=14%. When
forskolin was added to enhance the inhibitory response, normal
membranes gave a 22% inhibition with the addition of
dopamine while CJD membranes had virtually no change in
activity. Opiate added with GTP and forskolin gave an
inhibitory response in both CJD and normal: CJD=23% and
normal=21% inhibition.
This data suggests that the D2 (inhibitory) receptors are
affected in CJD. The fact that opiate elicited the same
inhibitory response in both CJD and normal membranes
indicates that the cyclase inhibitory mechanism is intact in CJD
and it contrary to our initial interpretation (see pg. 10).
Stimulation of both CJD and normal membranes by dopamine
indicates that the Dl receptor is intact. Normal membranes
have an inhibitory response to dopamine when enhanced by
forskolin, therefore dopamine is capable of inhibiting cyclase in
this membrane system. The decrease in inhibitory dopamine
action in CJD (and therefore unregulated stimulatory dopamine
component) may be responsible for some of the movement
disorders described in human victims of this disease
Other transmitters looked at included VIP, PIA, and PGEi.
These transmitters were examined under stimulatory
conditions (5mM MgCl2, Gpp[NH]p) and inhibitory conditions
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(ImM MgCl2, forskolin and GTP). These transmitters gave no
consistent effect on CJD or normal membranes. Since CJD
appears to affect the dopamine pathways, it is quite possible
that other transmitter pathways are also affected. Possibly
optimal conditions were not met for these transmitters
resulting in the lack of effect.
Membranes from regions of hamster and guinea pig were
assayed at various time points during disease incubation to
determine when the effects of CJD on adenylate cyclase become
evident. The time points chosen included pre-clinical (animals
showing no clinical symptoms of the disease) as well as
terminal (animals showing clinical symptoms) times. The time
points chosen were: Hamster: 8,12,16, and 18.5(terminal)
weeks, Guinea Pig: 12,15 and 22(terminal) weeks.
All membranes were frozen in liquid nitrogen and
assayed at the same time. Membranes were pre-incubated for
10 minutes at 30°C in Pre-incubation buffer containing 5mM
MgCl2, Gpp[NHlp 10-9 to 10"4M. Forskolin 10-^M and ethanol
500mM (3%) were added as required. Incubation Buffer was
added and reaction was incubated for 10 additional minutes at
the same temperature.
Guinea pig basal ganglia and hamster cortex were the two
tissues that consistently showed a greater stimulation of
Gpp[NH]p in CJD membranes as described previously. Thus
these regions were investigated in the time course experiment.
Normal stimulation was 2.1. The percent increase of
CJD/normal Gpp[NHlp stimulation at 12wk was 12%, at 15wk
was 16% and at 22wk was 16%. Hamster cortex also showed a
more pronounced progression in the degree of stimulation of
the CJD membranes. Normal was 4.5 fold and percent increase
of CJD/normal Gpp[NH]p stimulation at 8 wk was 10%, at 12wk
was 15% and 18.5wk (terminal) was 22%.
Forskolin was used not only to maximally stimulate
cyclase but also to enhance the detectability of inhibitory
components (Ni) of the system in these time course
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experiments. Since the stimulatory effect of Gpp[NH]p was not
consistently seen in many brain regions , forskolin was used to
effectively lower the "base line" and enhance the observed
stimulatory effect of Gpp[NH]p.
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FIGURE 10: Percent stimulation of Gpp[NH]p enhanced by forskolin
(Fsk+Gpp[NH]p/Fsk). 0 time indicates normal membranes with other points at the
indicated weeks of disease incubation. Normal hamster basal ganglia (day 0) was
not pre-incubated due to an oversight.
Through the incubation of the disease, Gpp[NH]p appears
to have an increasing stimulatory effect on forskolin modified
cyclase activity. Since the amount of catalytic unit is equal in
all regions by virtue of equal stimulation of Mn, the difference
in stimulation is likely due to the increased coupling of the Ns
subunit in combination with the forskolin effect on the catalytic
unit. The increase in coupling appears to progress as
incubation time increases. Infectivity studies of hamster
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cortical tissue using the side of the brain contralateral to the
one initially inoculated with infectious material show a rapid
increase in infectivity from 9.2 weeks to 15 weeks. After this
1.7 log rise, infectivity plateaus and remains relatively constant
until the terminal stages at 20 weeks (Manuelidis L.,
unpublished data). Earlier time points are needed to clearly
define the trend before the 8th week of incubation, but an
increase is stimulation is clearly evident until a plateau of
stimulation occurs at about 15-16 weeks in the basal ganglia of
both species. Interestingly the cortical tissues of both species
appear to continue to increase in stimulation up to the terminal
stages. The slight fall off in very terminal guinea pig basal
ganglia may be due to extreme destructive spongiform changes
at this time.
CONCLUSIONS
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We found that 1) adenylate cyclase is reproducubly
stimulated by non-hydrolyzable guanine nucleotides in CJD
significantly more than it is in control uninfected brain
membranes. Greater Gpp[NH]p cyclase stimulation in CJD as
compared with normal membranes was found in several brain
regions in guinea pig and hamster, although the magnitude of
the response varied from region to region. It appears that this
is due to a greater coupling of stimulatory subunits (Ns), and
not to a decreased coupling of inhibitory subunits (Ni). 2)
There was no evidence for any change in the functional
capacity of the cAMP catalytic unit in CJD membranes. 3) CJD
membranes give a greater fold cyclase stimulation as compared
to normal membranes under a variety of conditions. Although
there appears to be more activated Ns (GTP-Ns complex) in
membranes prepared from normal animals than in those
prepared from CJD infected animals, equalization of this effect
by pre-incubating membranes still yielded significant increases
in Gpp[NHlp stimulation in CJD. 4) CJD membranes appeared to
be more fluidized than normal membranes. Colchicine, tubulin
and amphotericin B had no further effects which rules out
involvement of filamentous proteins and cholesterol in the CJD
effect. 5) Experiments with selected neurotransmitters and
neuropeptides, indicated that only a sub-population of cyclases
(dopamine receptors) are involved in the CJD effect. Therefore,
although the magnitude of the fold stimulation increase in CJD
is often modest, albeit significant, it probably represents a
large magnitude change in a sub-population of cyclase
complexes. It is remarkable that many components of the
cyclase system remained completely functional in CJD since the
infectious agent targets membranes and leads to severe
neuronal membrane damage.
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The molecular mechanism of this effect remains to be
completely elucidated. However, it appears that in many brain
regions, there is an increase in membrane fluidity that allows
greater coupling of stimulatory subunits (Ns). This apparent
change in fluidity can account for the effect in hamster and
guinea pig cortex. In guinea pig basal ganglia (more so than in
hamster), there appears to be some additional molecular
process of unknown nature that may account for the majority
of the CJD effect observed. The basis of this fluidity change is
unknown. We were unable to document any indirect effect of
the cytoskeletal system on the membrane fluidity even though
morphologic studies suggest cytoskeletal system disruption in
spongiform encephalopathies (43).
Enhancement of Ns coupling as depicted through
increased fold stimulation of forskolin modified Gpp[NH]p
appears to begin at least as early as 8 weeks in hamsters and
12 weeks in guinea pigs but more extensive time course
studies are needed to assess the reproducibility or significance
of the CJD changes. Such changes if reproduced early in the
disease could be an important marker of infection when clinical
signs are not apparent.
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STUDENT RESEARCH PROGRAM
Thesis Requirement
HISTORY OF STUDENT RESEARCH AT YALE
There is a long tradition at Yale University School of Medicine
supporting the concept of medical student research. The first evidence
that the thesis or dissertation was considered a requirement for the
degree of Doctor of Medicine is in a statement in the catalog from 1839,
which in part reads, "- . . the candidate must present a dissertation on
same subject connected with the medical sciences." This requirement
remains in effect to the present time, and is enthusiastically endorsed
by the faculty as an important component of the "Yale System" of general
medical education.
In a survey of Yale Medical School graduates performed 26 years ago,
(with 1,034 of 1,206 graduates responding), 40% of graduates held
academic appointments and 61% had done research since graduation. The
experience in research during medical school was cited by graduates as a
critical factor in their choice of careers.
QiNKKAL ASPECTS OF CURRENT MEDICAL STUDENT RESEARCH PROGRAM
All students at Yale University School of Medicine engage in
research, with the exception of those students who have a Ph.D. degree
before matriculation. A wide choice of subjects for research is
permitted. Students may choose laboratory projects, or in many cases,
investigate clinical, epidemiologic, economic or historical topics. A
review of the literature or review of patients' charts may serve as a
source of data for research. One basic requirement applies to all
projects; there must be a hypothesis that can be supported or rejected by
the data that are generated. Data must be subjected to statistical
analysis, and results should either confirm or reject the original
hypothesis.
A close working relationship between student and research mentor is
a major goal of the program and is strongly encouraged. If laboratory
research is performed, it is the responsibility of the faculty advisor to
provide all necessary equipment and supplies. If the project is
concerned with clinical or epidemiological investigation, the same
commitment to guidance and support is expected. Weekly conferences
between student and advisor are encouraged during the course of the
research. The research must be designed and specifically performed by
the student with the advice of the faculty mentor. Students may not work
jointly on the research project.
The research is presented in written form during the fourth year and
must fulfil the following minimal requirements:
a. A critical review and citation of the work of previous
investigators.
b. A valid research design.
c. Evidence of the mastery of appropriate methodolgy.
d. Analysis of research data.
e. Conclusions that are supported by the data.
f . Summary (in abstract form) .
g. A literate presentation and correct bibliography.
Before the written report is presented to the Office of Student
Affairs, it must be approved by the student's advisor and a committee in
the department where the work was done.
An Awards Committee critiques and ranks all student theses submitted
for honors by various departments. The highest ranked papers are
presented in a student program chaired by the Dean of the School and
widely attended by students and faculty. Twelve prizes are awarded at
graduation for outstanding student research.
The creative discipline required to carry out a project and prepare a
thesis enables each student to become a physician-scholar whether the
ultimate objective is clinical practice, research, teaching, or admini
stration. Yale hopes to produce physicians who can evaluate data quickly
and critically as they must do throughout their professional careers.
SPECIFIC ASPECTS OF MEDICAL STUDENT RESEARCH PROGRAM
Many students begin research work during the summer following their
first year. In recent years the vast majority of first year medical
students have remained in New Haven to work with various faculty members
on a wide variety of projects. Stipends are available to support this
summer research. Many medical students continue their research work
afternoons, evenings, and weekends during the second year of medical
school. The Curriculum Committee has affirmed the desirability of
spending an additional six week block during the third year if students so
wish. Additional time is also available in mid-fourth year for completion
of research work. Thus a total of four to seven months is currently
available for research by each Yale student during the four years at
medical school.
The diagram below indicates the major blocks of free time in which a
student may complete a thesis.
Semester I Semester II Summer
Year I BASIC SCIENCES T
Year II BASIC SCIENCES NBI T or 1
Year UI2 345678 E/T
Year IV E/T E/T E/T E E E
NBI * Part I National Boards
1 thru 8 ■ Required six week clerkship rotations
E/T = Six week blocks available for elective and/or thesis time
In the fourth year, it is important that a project started at this
late date be one with reasonable expectation of completion and
acceptance. Some projects can be done at odd times, evenings and
weekends. The schedule shown above applies only to those projects that
require solid blocks of time.
A reminder; We recommend that the actual time devoted to data
collection (laboratory or other) be accomplished in a six-to eight-week
period or its equivalent in days. Additional time is needed for planning
and literature review, for evaluation of data, and final write-up.
One yp*T- medical student reseach fellowships
The School also encourages a few students to consider a fifth year of
medical school and devote it exclusively to research. This Student
Research Fellowship is facilitated by charging no tuition for the extra
year and by the provision of a limited number of stipends that can be
paid to students. These stipends will be available an a competitve basis
and students in any year are eligible to apply.
Getting started
A list of faculty members and their areas of research is available in
the Office of Student Affairs. After deciding upon the area of general
interest, the students should check with members of the faculty in both
the basic and clinical sciences who are working in that field. After
appropriate discussions, the student should choose the faculty member with
whom he/she wishes to work. Although it is not necessary that the idea
for the thesis originate with the student, it is necessary that the work
done be his/her own. The student can work as a member of a group project
only if the student's contribution is carried out on an independent basis.
Dissertations written jointly by two or more students are not acceptable.
There is no required length for the thesis. In planning a project it
should be clear that the prime goal is to learn the scientific method and
not necessarily to publish a paper. The faculty member should make every
effort to orient the student to a practical problem that can be fulfilled
within the available time.
Need for a Hypothesis
A review of the literature or a review of patients' charts may be the
source of data used for a thesis. However, the basic requirement still
applies. There must be a hypothesis which can be supported or rejected on
the basis of data gleaned from the patients' records and/or literature.
These data should be subjected to statistical analysis, and the results
should either oofinn or reject the original hypothesis. As with any other
thesis, a review of the literature and a section dealing with the
interpretation of the data and a discussion of its importance should be
included. A chart or literature review can not be a simple narrative
describing the information obtained from these sources.
vocj*A-rrh Involving human subjects
All research involving human subjects must be approved by the Human
Investigation Committee of the School of Medicine. Applications and
guidelines are available in the Office of the Chairman of the Committee.
Literature review and Protocol Formulation
When the area of investigation has been approved by the preceptor and
Departmental Thesis Committee the student .is expected to explore the
literature and formulate a protocol. This step provides an unusual
opportunity for tutorial instruction in experimental design. Faculty
members who assume responsibility as preceptors should take it seriously
and provide the amount of guidance in design of the investigation that is
necessary.
Joint Projects Not Acceptable
Dissertations written jointly by two or more students are not
acceptable. This does not mean that they may not work on related problems
but each student should have the experience of carrying out an investi
gation from beginning to end an his/her own initiative.
Research done outside of Yale Medical School
A student may wish to undertake his/her research project under the
supervision of a qualified investigator who is not a member of the faculty
of Yale University School of Medicine. The approval of an outside
preceptor will be granted by the Dean's office upon receipt of a statement
by a senior faculty member acting as sponsor, in whose area the research
work will be done. The statement should indicate the sponsor has approved
the preceptor and the facilities available for the research project. The
same regulations <ox>ncerning the dates of submission and review by the
appropriate departmental committee will apply to the thesis done outside
of the medical school.
Ph.D. Thesis in lieu of Medical School Thesis
For students enrolled in the combined M.D./Fh.D. program, the doctoral
thesis submitted to and approved by the Graduate School will serve in lieu
of the thesis requirement of the Medical School. For students in the
M.D./M.P.H. program, the medical school requirement applies.
Typing and Binding Costs
The cost of typing and binding the dissertation is the responsibility
of the student. Departmental or research funds should not be used for
this purpose.
Statistical Analysts
When the results of an investigation lend themselves to statistical
analysis the student should be encouraged to seek the aid of a biometrist
for assistance in statistical methodology. It is hoped that this will
enable the student to learn the value and limitations of statistical
analysis as an aid in interpreting the results of an investigation.
Typing and Assembly Instructions
The thesis should be typed, double spaced, an a good 20 pound weight
paper with a 1-1/2 inch left hand margin. All other margins may be one
inch. Single spacing may be used within (double spacing between) block
quotations, footnotes and bibliography. Corrasable bound is not
acceptable. You will need an original and at least two copies (one copy
for the department chairman's office and one copy for your advisor) . The
copies should be reproduced on a good copying machine. The original or
best copy must be bound with a hard cover, any color. The other copies
may be bound with soft covers.
The Office of Student Affairs has lists of typists, copying and
binding services. A thesis which contains strikeovers, messy erasures,
and careless spacing and centering, or in which the fundamentals of
punctuation and spelling are not observed, may not be accepted.
The title, the student's full name and the year of the degree must be
imprinted on the cover, and the student's last name and abbreviated title
on the spine.
If charts, graphs, maps, tables or computer printouts that are larger
than the standard page size are to be used, they should be folded
carefully into the manuscript, with the fold at least 1/2 inch from the
right hand edge of the page.
Each page in the thesis should be numbered except the title page
(sample attached) , abstract, acknowledgements and table of contents. The
number should be placed either at the top center (approximately 4 lines
from the top of the page) or at the top right hand corner (approximately 4
line from the right edge of the paper) .
The abstract should be headed as follows:
ABSTRACT
FULL TITLE OF DISSERTATION (as on title page)
Full Legal Name (inclining middle name)
Year (of graduation)
Legends are placed below the illustrative material. A legend may
appear, however, an a facing legend page when both illustration and the
legend cannot be acxxennodated an one page.
To mount photographs, use Duco or equivalent cement, rubber cement or
"permanent" glue. Regular glue, picture corners and adhesive cellophane
are not acceptable.
Title Page Format
(Title of Dissertation)
A Thesis Submitted to the Yale University
School of Medicine in Partial Fulfillment
of the Requirements for the Degree of
Doctor of Medicine
by
(Legal name of author)
(Year of degree)
APPROVAL PROCESS
The Thesis Subcommittee of the Curriculum Committee:
A Thesis Subcommittee of the Curriculum Committee has been formed and
meets regularly to recommend policy to the Curriculum Committee for all
aspects of the Thesis requirement. Specifically, rules and regulations
will be set and deadlines established. The committee will serve as a
reviewing body to determine prizes and guidelines for the awarding of
prizes.
Office of Student Research
The Chairman of the Thesis Subcommittee will also establish an office
dedicated to student research where lists of preceptors will be kept up to
date; where advice can be given to students searching for research
projects; where information about past student projects can be kept; and
where sources of funds can be filed and organized in such a way that
timely applications can be made. For the present this office will be in
the Office of Student Affairs under the direction of Dr. John Forrest.
Departmental Thesis Committees
Each department chairman will appoint a Departmental Thesis Committee
of three senior faculty members who will be responsible for approving
completed dissertations done within that department.
Outline of Proposal must be Approved
Each student will prepare an outline of his/her proposed research
project. This outline will include a title, a brief outline of the
project (including an hypothesis) , the data .that will be obtained to
support the hypothesis and the resources available. In addition, it will
include an estimate of the time necessary to accomplish the project. This
resume will be signed by the student and approved by his/her advisor and
spjbmitted to the Departmental Thesis Committee six to eight weeks before
the proposed starting date of the research project. The Departmental
Thesis Committee will return the document to the student with their
approval and/or reason for rejection. The review by the Departmental
Thesis Committee will determine if the general scope of the work and
resources available are consonant with the traditional Yale thesis
requirement. The Committeee is not being asked for advance approval of
the project.
Each student must have prepared this resume, obtained approval from
his/her faculty advisor and submitted it to the Departmental Thesis
Committee for review no later than May 1 of the third year. In the case
of those who are spending more than four years in Medical School, the
deadline will be May 1 preceding the final year.
Tnesis approval and Deadlines
Early in the fourth year, at the time of the interview with the Dean
of Students a^Kc^rning postgraduate training, each student will submit a
progress report describing the status of the research project and the
anticipated date of completion. This brief document will be signed by the
advisor and the student.
A draft of the thesis project must be submitted to the advisor by
February 2, of the year of graduation.
Before a thesis is presented to the Office of Student Affairs, it must
be approved by the student's advisor and a thesis committee in the depart
ment where the work has been done. It is not sufficient that the thesis
be approved only by the student's advisor.
If changes are suggested by the departmental committee, these will be
explained to the student and his/her advisor, and revisions made if
necessary.
If the thesis is to be considered for an award or presentation of
Student Research Day, it must be submitted to the Departmental Thesis
Committee by F^n-maTy 16 and to the Office of Student Affairs by March
16. Departmental Thesis Committees nominate student theses for prizes
with recommendation of the student's advisor.
When approved, the thesis should be typed in the format stated
previously and presented to the Office of Student Affairs no later than
March 16. accompanied by a letter stating that it has been approved by the
Department. Extensions will be granted only on approval of the advisor
and the Departmental Thesis Committee Chairman. Under no circumstances
will any thesis be received by a department after April 1. with a bound,
approved thesis to the Office of Student Affairs by May 1. Students
missing these later deadlines will not graduate in May of that year.
The dates set in the fourth year are not arbitrary ones. Granting of
the M.D. degree by the University is approved by the Board of Permanent
Officers of the Medical School and the Yale Corporation. Your name cannot
be presented to the Board of Permanent Officers until all of the
requirements for the degree have been fulfilled; your name cannot be
presented to the Yale Corporation until it has been approved by the Board
of Permanent Officers. These two bodies do not meet frequently and the
timing of their meeting with the date of Ccnimencement necessitates our
setting real deadlines.
YALE UNIVERSITY SCHOOL OF MEDICINE
OFFICE OF STUDENT AFFAIRS
L205 SHM
MEMORANDUM
February 1 , 1 988
To: Class of 1 988
From; Betsy Winters
Attached is a release form to allow photocopying of
your thesis for educational purposes in future years. If
you would like to have this permission included with your
thesis in the Medical Library, please return the form to me
by May 21. This is entirely optional.
MO
att.
Permission for photocopying or microfilming of "
ii
(Title of thesis)
for the purpose of individual scholarly consultation or refer
ence Is hereby granted by the author. This permission is not
to be interpreted as affecting publication of this work or
otherwise placing it in the public domain, and the author re
serves all rights of ownership guaranteed under common law
protection of unpublished manuscripts.
Signature of Author
Date


3 9002 01012 9899
fALt MEDK-AA
YALE MEDICAL LIBRARY
3 9002 01041 2634
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Manuscript Theses
Unpublished theses submitted for the Master's and Doctor's degrees and
deposited in the Yale Medical Library are to be used only with due regard to the
rights of the authors. Bibliographical references may be noted, but passages
must not be copied without permission of the authors, and without proper credit
being given in subsequent written or published work.
This thesis by has been
used by the following persons , whose signatures attest their acceptance of the
above restrictions.
NAME MD ADDRESS DATE

